Table 2. Histopathological findings.
MALE | FEMALE | |||||||
---|---|---|---|---|---|---|---|---|
Parameters | 4 weeks | 8 weeks | 12 weeks | 16 weeks | 4 weeks | 8 weeks | 12 weeks | 16 weeks |
Steatosis Grade (0–3) | 1 (33%); 2(66%) | 2 (100%) | 2 (100%) | 2 (33%); 3 (66%) | 2 (100%) | 2 (100%) | 2 (33%); 3 (66%) | 1 (29%); 2 (71%) |
Location (score 0–3) | 2; Azonal | 2; Azonal | 2; Azonal | 3; Paracinar | 2; Azonal | 2; Azonal | 2 (33%); Azonal. 3 (66%); Paracinar | 1 (29%); periportal. 2 (71%); Azonal |
Portal Inflammation (score 0–1) | 0 (100%) | 0 (66%); 1 (33%) | 0 (100%) | 0 (62%); 1 (28%) | 0 (66%); 1 (33%) | 0 (66%); 1 (33%) | 0 (66%); 1 (33%) | 0 (58%); 1 (42%) |
Lobular Inflammation Score (0–3) | 0 (66%); 1 (33%) | 0 (33%); 1 (33%); 2 (33%) | 0 (33%); 1 (66%) | 0 (15%); 1 (85%) | 0 (33%); 1 (66%) | 0 (33%); 1 (66%) | 0 (33%); 1 (66%) | 0 (72%); 1 (28%) |
Fibrosis Stage (0–4) | 0 (66%); 1a (33%) | 1b (66%); 1c (33%) | 1a (33%); 1c (66%) | 1a (14%); 2 (86%) | 0 (66%); 1a (33%) | 1a (66%); 1b (33%) | 1a (33%); 1b (33%); 2 (33%) | 1b (14%); 1c (71%); 2 (15%) |